Submit Manuscript  

Article Details


The Bleeding Risk in Antithrombotic Therapies: A Narrative Review

Author(s):

Adriano Alatri and Lucia Mazzolai*   Pages 1 - 12 ( 12 )

Abstract:


Bleeding represents the most important complication of antithrombotic treatment, including anticoagulant and antiplatelet therapies. A number of scores were proposed to evaluate the risk of bleeding both for anticoagulant and antiplatelet treatment. In the last decade, 5 bleeding risk scores were published for use in atrial fibrillation patients, and 3 scores for patients receiving anticoagulants for venous thromboembolism therapy or prophylaxis. In addition, 3 scores were recently developed to assess inhospital or short-term bleeding risk in patients receiving antiplatelet therapy after acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). Furthermore, 3 additional scores have focused on long-term bleeding in outpatients receiving dual antiplatelet therapy after PCI. The aim of this review is to consider the evidence on bleeding scores.

Keywords:

Bleeding, clinical predictive rules, atrial fibrillation, venous thromboembolism, acute coronary syndrome, percutaneous coronary intervention, anticoagulants, antiplatelet therapy.

Affiliation:

Division of Angiology, Heart and Vessel Department, Lausanne University Hospital, Lausanne, Division of Angiology, Heart and Vessel Department, Lausanne University Hospital, Lausanne



Read Full-Text article